Skip to main content

Table 4 Number and percentages of suspected ACT reported to UMC clustered according to the country priority groups from 2001 to 2008

From: Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring

 

Priority 1 countries

Priority 2 countries

Priority 3 countries

All reporting countries

Number of suspected ACT

40 1

11 2

9 3

60

% of total number of suspected ACT

67%

18%

15%

100%

  1. Note: ACT, Artemisinin-based combination therapy; SSA, sub-Saharan Africa
  2. 1 Reports have been submitted by Ghana and Tanzania
  3. 2 Reports have been submitted by Nigeria and South Africa
  4. 3 Reports have been submitted by France, Germany, the Netherlands, Switzerland and United States